Jump to top menu Jump to main menu Jump to content
Research group/lab  |  Prof. Dr. Ron H.N. van Schaik

Pharmacogenetics International Expertcenter

Research is aimed at discovery and implementation of DNA analysis for personalizing drug therapy

About our research group/lab

Our research


Research of the group has a focus on the value and subsequent clinical implementation of  pharmacogenetics. Current topics are:

  1. Oncology (capecitabine, irinotecan, paclitaxel, docetaxel, tamoxifen, nivolumab, pembrolizumab)
  2. Immunosuppressants (tacrolimus, cyclosporine, MMF)
  3. Opioids (morphine, tramadol, propofol, oxycodone).
  4. Antidepressants/antipsychotics


Opioid dependency

Very recent, a 16 gene panel has been introduced to the FDA to be able to predict opioid dependency. We are investigating the clinical validity of this test, and its implementation to control the widespread opioid dependency in The Netherlands. For this, we have a close and exclusive collaboration with a US based company.


Cell free DNA

A new, non-invasive and sensitive biomarker approach is to make use of the detection of DNA variants in blood:  cell free DNA analysis. We investigate this approach in three research lines:

  1. NSCLC. Analysis of EGFR T790M, L858R, exon19 skipping and C797S mutations can guide decisions on the use of osimertinib.
  2. Prostate cancer. Analysis of exosomal RNA of the AR-V7 transcript has added value in the treatment of castrate resistant prostate cancer
  3. Heart/kidney transplantation. Monitoring of graft rejection by using cfDNA techniques.


Prostate cancer & Cardiac Biomarkers

This research is focusing on new markers for the early detection of  prostate cancer (collaboration with Dept. Urology, Prof. Chris Bangma) and new markers for the early detection of acute myocardial infarction (collaboration with Dept. Cardiology, Prof. Eric Boersma).

Key Publications

1. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.. Henricks LM(1), Lunenburg CATC(2), de Man FM(3), Meulendijks D(4), Frederix GWJ(5), Kienhuis E(3), Creemers GJ(6), Baars A(7), Dezentjé VO(8), Imholz ALT(9), Jeurissen FJF(10), Portielje JEA(11), Jansen RLH(12), Hamberg P(13), Ten Tije AJ(14), Droogendijk HJ(15), Koopman M(16), Nieboer P(17), van de Poel MHW(18), Mandigers CMPW(19), Rosing H(20), Beijnen JH(21), Werkhoven EV(22), van Kuilenburg ABP(23), van Schaik RHN(24), Mathijssen RHJ(3), Swen JJ(25), Gelderblom H(2), Cats A(26), Guchelaar HJ(25), Schellens JHM(27). Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19. (IF 35.4)

2. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Goetz MP(1), Sangkuhl K(2), Guchelaar HJ(3), Schwab M(4)(5)(6), Province M(7), Whirl-Carrillo M(2), Symmans WF(8), McLeod HL(9), Ratain MJ(10), Zembutsu H(11),Gaedigk A(12), van Schaik RH(13)(14), Ingle JN(1), Caudle KE(15), Klein TE(2). Clin Pharmacol Ther. 2018 Jan 31. doi: 10.1002/cpt.1007. [Epub ahead of print] (IF 6.3)

3. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Del Re M(1), Biasco E(2), Crucitta S(3), Derosa L(2), Rofi E(3), Orlandini C(2),Miccoli M(4), Galli L(2), Falcone A(2), Jenster GW(5), van Schaik RH(6), Danesi R(3). Eur Urol. 2017 Apr;71(4):680-687. doi: 10.1016/j.eururo.2016.08.012. Epub 2016 Oct 10. (IF 17.3)

4. CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Elens L, Nieuweboer A, Clarke SJ, Charles KA, de Graan AJ, Haufroid V, Mathijssen RH, van Schaik RH.. Pharmacogenomics. 2013 Jan;14(2):137-49. doi: 10.2217/pgs.12.202. (IF: 4.0)

5. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.. Schröder FH(1), Hugosson J(2), Roobol MJ(3), Tammela TL(4), Zappa M(5), Nelen V(6), Kwiatkowski M(7), Lujan M(8), Määttänen L(9), Lilja H(10), Denis LJ(11), Recker F(12), Paez A(13), Bangma CH(3), Carlsson S(14), Puliti D(5), Villers A(15), Rebillard X(16), Hakama M(17), Stenman UH(18), Kujala P(19), Taari K(20),Aus G(21), Huber A(22), van der Kwast TH(23), van Schaik RH(24), de Koning HJ(25), Moss SM(26), Auvinen A(27); for the ERSPC Investigators. Lancet. 2014 Aug 6. pii: S0140-6736(14)60525-0. doi: 10.1016/S0140-6736(14)60525-0. [Epub ahead of print] (IF 59.1)


Collaborations within Erasmus MC:

Hospital Pharmacy, Medical Oncology, Internal Medicine, Psychiatry, Urology, Children’s Surgery, Cardiology


Collaborations outside of Erasmus MC


University of Pisa – Prof Romano Danesi, Dr Marzia del Re

University of Estonia – Prof Lili Milani

Georgetown University – Prof John van den Anker

University of Patras – Prof George Patrinos

Thrace University Alexandropoulis – Prof Vangelis Manolopoulos



CZ Insurrances

STAR-SHL – Marieke van Schaik, Wim Rutten

LUMC – Prof Henk-Jan Guchelaar, Dr Jesse Swen

Radboud University –

UMC Utrecht – Dr Maarten ten Berg, Dr Vera Deneer

Amsterdam UMC – Prof Robert de Jonge

NKI Amsterdam – Dr Daan van den Broek, Prof Gerrit Meijer

UMC Groningen – Prof Ed Schuuring

Our team

Ron van Schaik, Prof. Dr. – PI

Maja Matic, Dr. – Post Doc

Mirjam de With – PhD student

Evert de Jonge – research technician

Samira el Bouazzaoui – research technician

Iris Smits - research technician

Tessa Mulder - research technician

Sanne Suijker - resident


Contact us